1 of 1
Story summary
- Novo Nordisk will cut U.S. list prices for Ozempic, Wegovy, and Rybelsus by up to 50% beginning January 1, 2027, with a new price of $675 per month.
- The reduction aligns with Medicare pricing changes and aims to improve affordability amid rising competition in the weight-loss drug market.
- Jamey Miller, Novo Nordisk’s head of U.S. operations, said the move addresses demands for lower prices amid a shift toward consumer-driven healthcare.
